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Background: Clozapine effectiveness in the treatment of refractory schizophrenia has been sustained by published
evidence in the last two decades, despite the introduction of safer options.
Discussion: Current clinical practice guidelines have strongly recommended the use of clozapine in treatment-resistant
schizophrenia, but prescribing trends do not appear to have followed such recommendations. Clozapine is still
underutilized especially in patients at risk of suicide. It seems that physicians are hesitant in prescribing clozapine
due to concerns about serious adverse effects. Recent reports have highlighted the need to inform health professionals
about the benefits of treating patients with clozapine and have voiced concerns about the underutilization of clozapine
especially in patients at risk of suicide.
Summary: Guidelines and prescribing patterns reported in various countries worldwide are discussed. Suggestions on
how to optimize clozapine utilization have been published but more efforts are needed to properly inform and support
prescribers’ practices.
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Clozapine efficacy as an “atypical” antipsychotic agent has
been recognized since the early 1960s [1]. This agent be-
came available on the European market for the treatment
of schizophrenia with the promise of a better tolerability
because of the absence of those extrapyramidal side effects
that afflicted patients treated with other antipsychotic
agents (e.g., chlorpromazine and haloperidol, now defined
as “typical” or first- generation agents, FGAs) [1]. However,
the release of alarming reports of agranulocytosis in Finnish
patients created panic among prescribers; a total of 17 cases
were confirmed among 100 patients treated with clozapine,
8 of those cases resulted in fatalities. Clozapine was imme-
diately withdrawn from the market by Sandoz (1976) [1].
It was not until fourteen years after its withdrawal that
the results of the pivotal US Clozaril Study were pub-
lished and the important role of clozapine in clinical
practice was discovered [2]. Clozapine demonstrated su-
periority to chlorpromazine in treatment-resistant pa-
tients in many outcomes including treatment response,* Correspondence: Silvia.Alessi-Severini@umanitoba.ca
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distribution, and reproduction in any mediumwith improvements in positive and negative symptoms
of schizophrenia [2]. This led health agencies to grant
clozapine access to the US and Canadian markets in
1990 and 1991, respectively.
The recognized risk for agranulocytosis, assessed at a
prevalence of 1-2%, has been managed since then by
mandatory monitoring systems administered by the manu-
facturers of the clozapine products (now generized in most
countries) to assure that patients undergo routine blood
testing before each dispensation. Current product mono-
graphs mandate that patients start therapy gradually and
that normal WBC and absolute neutrophil counts (ANC)
are maintained at safe levels (WBC count ≥3500/mm3 and
ANC ≥2000/mm3) throughout treatment [3]. Thus, pa-
tients at risk of developing agranulocytosis can be identified
before the condition becomes life-threatening. The imple-
mentation of registries for the monitoring of hematological
toxicity has in fact significantly reduced mortality and mor-
bidity in patients treated with clozapine [4].
The 1990s saw also the introduction of other new
“atypical” antipsychotics (e.g., risperidone, olanzapine, que-
tiapine also identified as second-generation agents, SGAs).
These agents, developed to obtain efficacious medications
similar to clozapine without the hematological toxicity,ioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Life (QoL) in patients affected by schizophrenia. Early
studies of SGAs demonstrated superiority over the FGAs,
including a lower incidence of EPS, superior efficacy for
positive, negative and mood symptoms, improved tolerabil-
ity, as well as cognitive enhancing effects [5-8]. Despite
higher costs, SGAs were widely adopted worldwide [9-12].
However, none of the newer SGAs could demonstrate
superiority to clozapine and in the last decade many pub-
lished clinical practice guidelines [13-20] have recom-
mended that clozapine be prescribed to patients with
treatment-resistant schizophrenia, which has been defined
as not responsive to two trials of any other antipsychotic
medication (either FGA or SGA). Despite such recommen-
dations and the overwhelming evidence of clozapine effect-
iveness, prescribing of clozapine appears to be low, delayed
and often preceded by attempts at polypharmacy treatment,
which lacks clinical evidence of effectiveness [21-26].
Aim and scope
The main objectives of this article are to provide infor-
mation on clozapine place in therapy and to discuss clo-
zapine’s prescribing trends since the publication of the
most recent schizophrenia clinical practice guidelines in
North America and Europe.
Methods
Clinical practice guidelines, meta-analyses, and reports on
clozapine prescribing trends have been identified from
searches in PubMed, Psychinfo, EMBASE and Cochrane
databases. The search was focused on publications in the
last 10-year period (2004 and 2014). Articles selection was
limited to those written in the English language. Individual
clinical trials and older landmark studies have been cited
where appropriate. Keywords used in the literature




Clozapine effectiveness was initially demonstrated against
chlorpromazine, the prototype of the FGAs [2]. Evidence of
clozapine advantage over FGAs has been well established
and results of various trials, conducted mostly in the 1990s,
have been included in meta-analyses [27-29]. The conclu-
sions were that clozapine was more effective than FGAs in
reducing symptoms of schizophrenia according to measure-
ments of BPRS scores and SANS negative symptoms
scores. Clozapine produced clinically meaningful improve-
ments and postponed relapse [30-32].
Clozapine vs. SGAs
The landmark study CUtLASS 2 found that in patients
failing to respond to two or more antipsychotics, clozapineproduced significant improvement in symptoms over
1 year [33]. The phase 2E CATIE study revealed that clo-
zapine was significantly more effective than quetiapine
and risperidone, and the authors concluded that in pa-
tients with an insufficient therapeutic response to a SGA,
clozapine was more effective than switching to a different
SGA [34-36].
More recent evidence has confirmed clozapine super-
iority to other SGAs and olanzapine [37,38].
Clozapine effectiveness on mortality
Effects of clozapine treatment on patient mortality has been
assessed and reviewed over the years in various populations.
The evidence supports a clear advantage of clozapine ther-
apy in terms of reduced mortality over other antipsychotic
agents including FGAs, risperidone and quetiapine [39-42].
Clinical practice guidelines and algorithms
The evidence produced in the last 20 years, and summa-
rized by published clinical practice guidelines and algo-
rithms, has confirmed clozapine to be the gold standard for
treatment-resistant schizophrenia. Please refer to Table 1
for a summary of recommendations.
Clozapine prescribing trends
Treatment-resistant schizophrenia has been established to
affect 20-30% of all patients diagnosed with schizophrenia
[21,31]. Nevertheless, physicians’ prescribing practices re-
veal that only a small portion of patients with treatment-
resistant schizophrenia are treated with clozapine [21]. In
1999, only 160,000 US patients of the 2.6 million diagnosed
with schizophrenia were treated with clozapine (only 25%
of treatment-resistant patients) [21]. Since the introduction
of the newer SGAs, clozapine use decreased in the United
States: in 1999, clozapine represented 11% out of the total
SGAs prescribed, which steadily decreased to less than 5%
in 2002 [21]. During phase 3 of the CATIE study, 51% of
patients had previously discontinued medications due to in-
effective therapeutic response, but only 11% of patients
were offered clozapine during phase 3. Studies of clozapine
utilization have shown that adherence to guidelines has
been poor through the years with clozapine been consist-
ently underutilized in the US, UK, Canada, New Zealand
and Australia [9,21-26,42-46]. In a study of the Veterans
Health Administration, only 2% of patients affected by
schizophrenia were receiving clozapine [22].
Adherence to treatment guidelines in the UK was also
very poor in terms of clozapine initiation as in more
than 34% of patients’ polypharmacy and high dose treat-
ments were used before commencing clozapine [23].
Recent Canadian statistics, based on physician drug
recommendations from 2005 to 2009, show a 48% in-
crease in clozapine recommendations over a 5-year
period [10]; however, a more recent report determined
Table 1 Summary of evidence-based recommendations for clozapine prescribing
Date Source Recommendation: clozapine to be
prescribed or offered to patients
After failure of 2 adequate
trials of 2 different AAs
With suicidal thoughts
or behaviours
With persistent hostility and
violent behaviours
2004 APA (US) [13] X
2005 CPA (CAN) [14] X
2007 TMAP (US) [15] X (SGAs considered first-line)
2009 NICE (UK) [16] X (at least one of the drugs should
be a non-clozapine SGA)
2010 Schizophrenia PORT (US) [17] X X X
2010 CADTH [18] X
2011 BAP (UK) [19] X X
2013 PAP (US) [20] X (SGA, risperidone and olanzapine)
considered first-line)
X X
Note: AA = antipsychotic agent, APA = American Psychiatric Association, BAP = British Association for Psychopharmacology, CADTH = Canadian Agency for Drugs
and Technology in Health, CPA = Canadian Psychiatry Association, PAP= Psychopharmacology Algorithm Project, PORT = Patient Outcomes Research Team, TMPA= Texas
Medication Algorithm Project.
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more antipsychotics before switching to clozapine [26].
In contrast, clozapine utilization in Australia appears to
be more appropriate with a percentage as high as 51% of
clozapine use in treatment-resistance schizophrenia [46].
Discussion
Despite the long and still ongoing debate about the com-
parative safety and effectiveness of FGAs and SGAs
[5,6], during the last two decades, clozapine has main-
tained its place in therapy as the treatment of choice in
refractory schizophrenia (third-line agent). It has also
been suggested that earlier use (as a second line agent)
can be recommended in individuals with persistent hos-
tility/aggressive behaviour [47] and suicidalilty [39-42].
In fact the indication for recurrent suicidal behavior has
been officially approved by the FDA [48]. Its role in
first-episode and non-treatment-resistant patients has
been investigated [49-53] and while further research in
the area of early onset schizophrenia and time to treat-
ment response is needed [54-57], clozapine value as a
second line agent has been recently recognized in a first-
episode schizophrenia population [58].
While clinical practice guidelines have strongly en-
dorsed clozapine as the gold standard of therapy, its use
has been lower that recommended. Reasons for physi-
cians’ reluctance to prescribe clozapine have been evalu-
ated and the relatively high incidence of agranulocytosis
has certainly had great influence; however, the careful
monitoring of WBC counts and ANC has almost com-
pletely abolished the risk of fatal agranulocytosis; fre-
quency of blood tests has recently been simplified and
once WBC counts and ANCs have been maintained
within normal levels for one year, blood tests are now
only required once every 4 weeks [27,47]. It is also ofimportance to note that in some European countries a
more flexible monitoring schedule, which can be re-
duced to quarterly blood testing in individuals not at
risk, has been proposed [59,60].
Concerns over other adverse effects, which include
weight gain, hyperglycemia, seizures, tachycardia, myo-
carditis and neuromalignant syndrome [61], can affect
the decision making process and even less severe side ef-
fects (sedation, constipation, nocturnal hypersalivation)
might result in patients’ resistance to try this medication
[42,62]. Clozapine has shown, however, a definite advan-
tage in reversing tardive dyskinesia [13,17,34,58]. Sug-
gestions on how to balance safety and effectiveness of
clozapine have been given [63]. Other issues can be seen
in the added costs associated with blood monitoring and
health care system contacts due to the need for gradual
titration of clozapine therapy, however, clozapine cost-
effectiveness has been consistently shown over other
agents [64,65]. Recent reports have highlighted the need
to inform health professionals about the benefits of
treating patients with clozapine [24,66-69] and have
voiced concern that clozapine is still under utilized espe-
cially in patients at risk of suicide [66]. Interprofessional
practice models that see pharmacists being more in-
volved in patient care have been advocated to improve
and optimize prescribing of clozapine [70].
Summary
 Published clinical evidence has supported clozapine as
the gold standard in the treatment of refractory
schizophrenia as it is reflected in the recommendations
of many clinical practice guidelines.
 Clinical practice guidelines, however, do not appear
to have been followed by prescribers and clozapine
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with treatment-resistant schizophrenia.
 Efforts are needed to encourage and optimize
clozapine utilization.
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